https://africanjournalofbiomedicalresearch.com/index.php/AJBR
Afr. J. Biomed. Res. Vol. 27(4s) (December 2024); 6175-6178
Research Article

Erythravine And Other Isoflavanoids: Their Potential in Neuroprotection and Stroke Therapy

Chandarana Sanjana[1]*, Dr. Pragnesh Patani[2], Dr. Shweta Paroha[3], Dr. Nishkruti Mehta[4], Hetvi Shah[5]

[1*]Department of Pharmacology, Khyati College of Pharmacy, Palodia, Ahmedabad
[2]Principal and Professor, Department of Pharmacology, Khyati College of Pharmacy, Palodia, Ahmedabad
[3]Associate Professor, Department of Pharmaceutics, Khyati College of Pharmacy, Palodia, Ahmedabad
[4]Professor, Department of Pharmacology, Khyati College of Pharmacy, Palodia, Ahmedabad
[5]Department of Pharmacology, Khyati College of Pharmacy, Palodia, Ahmedabad

***Corresponding Author:** Chandarana Sanjana
*Department of Pharmacology, Khyati College of Pharmacy, Palodia, Ahmedabad
*Email: sanjanachandarana48@gmail.com

Abstract
The growing body of literature on neuroprotective effects and therapeutic potential for stroke treatment not just in erythravine but also other isoflavonoids especially produced from Erythrina mulungu, has raised the possibility that these molecules can be a good source of fine chemicals [18]. Reviewing erythravine and its derivatives, a group of compounds with anticonvulsant effects based on numerous preclinical studies, this article summarizes the pharmacological features displayed by these drugs. The strong immunity of (+)-11-α-hydroxy-erythravine and (+)-erythravine against chemically induced seizures deserves special attention, suggesting effective proteolytic actions without affecting glutamate or GABA pathways directly. This article discusses one of the mechanisms behind these effects: regulation by nicotinic acetylcholine receptors, which could play a role in their anxiolytic and neuroprotective properties.
Moreover, the reviewers also note an important point of this study which is its broader implications for stroke therapy as a whole — how natural phytocompounds (such as erythravine) may serve to function in place of current therapies with similar efficacy yet reduced induction of side effects. Through combining data from neurochemical and electrophysiological experiments, the study provides a comprehensive analysis of erythravine´s functionality as a Neuroprotective agent and represents an initial step towards further investigations about its clinical relevance in stroke and other neurological pathologies.

***Authors for correspondence: Email:** *sanjanachandarana48@gmail.com*

Received:02/11/2024 *Accepted: 03/12/2024*

DOI: https://doi.org/10.53555/AJBR.v27i4S.4753

© 2024 The Author(s).
This article has been published under the terms of Creative Commons Attribution-Noncommercial 4.0 International License (CC BY-NC 4.0), which permits noncommercial unrestricted use, distribution, and reproduction in any medium, provided that the following statement is provided. "This article has been published in the African Journal of Biomedical Research"

1. Introduction

Stroke is the second leading cause of death globally and a significant contributor to long-term disability, making it a critical public health issue[1]. Approximately 12.2 million people experience strokes each year, with ischaemic strokes accounting for about 87% of these

cases, according to the Global Burden of Disease Study[2]. Iadecola and Anrather (2011) explain that the pathophysiology of stroke involves a complex interplay of ischaemia, oxidative stress, inflammation, and apoptosis, [6]ultimately leading to neuronal damage and cell death. Given that stroke is a prevalent medical condition with severe consequences, it is essential to develop effective neuroprotective strategies to minimize neuronal damage and promote recovery[3].

1.1. Neuroprotection: A Medical Strategy

Neuroprotective measures refer to strategies aimed at preserving neuronal structure and function in the face of disease or injury. This concept has gained traction in stroke treatment as researchers seek compounds that can mitigate the detrimental effects of ischaemia. Traditional therapeutic approaches have primarily focused on acute interventions like thrombolysis and thrombectomy; however, these methods come with limited time frames and significant risks[5]. Consequently, there is a growing interest in pharmaceuticals that target the underlying mechanisms of neuronal damage and provide neuroprotection.

1.2. Isoflavonoids: A Group of Organic Substances

Isoflavonoids, a subgroup of flavonoids, are primarily found in legumes, particularly soybeans. They exhibit a range of biological activities, including neuroprotective, anti-inflammatory, and antioxidant effects[6]. Among these compounds, erythravine is notable for its potential in neuroprotective therapies. This alkaloid, derived from the Erythrina species, has been used for its medicinal properties across various cultures[7]. Its ability to modulate neuroinflammatory processes and shield against oxidative stress makes it a promising candidate for stroke treatment.

2. Methods

2.1. Cell culture models used in in vitro studies:

- Neuronal cell lines like SH-SY5Y will be utilized to assess the cytotoxic effects of erythravine and other isoflavonoids[8].

Mechanistic Research:

- Apoptosis Assays: Annexin V/PI staining followed by flow cytometry will be employed to evaluate apoptosis induction[9].
- Determining Oxidative Stress: Reactive oxygen species (ROS) will be quantified using DCFDA assays post-treatment[10].
- Western Blotting: The expression levels of neuroprotective proteins (e.g., caspases, Bcl-2) will be analyzed to elucidate the involved signaling pathways[8].

2.2. In Vivo Research Animal Models:

- Rodent ischemic stroke models, such as middle cerebral artery occlusion, will be used[11].
- Erythravine will be administered orally or intravenously at varying doses (e.g., 10 mg/kg to 50 mg/kg) before and after stroke induction[12].

Behavioural Evaluations:

- Neurological deficits will be assessed using a modified neurological severity score and motor function tests like the rotarod test following treatment[10].

2.3. Research on Pharmacokinetics Evaluation of Bioavailability:

- After administering erythravine to animal models, plasma concentrations should be measured using LC-MS/MS[13].
- The pharmacokinetic parameters, including half-life, time to peak concentration (Tmax), and peak plasma concentration (Cmax), need to be calculated[11].

2.4. Design of Clinical Trials:

- Conduct double-blind, randomized, placebo-controlled trials to evaluate the effectiveness of erythravine in stroke patients[13].
- The primary focus of the inclusion criteria should be adult patients diagnosed with ischaemic stroke within a specific time frame after onset (e.g., within 24 hours)[10].

Final Points:

- One of the primary endpoints may be the modified Rankin Scale, which assesses functional outcomes 90 days post-therapy[13].
- Secondary outcomes could include the incidence of side effects and evaluations of quality of life[13].

2.5. Data Analysis Statistical Methodologies:

- For statistical analysis, utilize software such as R or SPSS[12].
- When comparing two groups, apply t-tests and set the significance level at $p < 0.05$ by conducting an ANOVA[10].

3. Discussion

This discussion covers the mechanisms of action of erythravine, its role in neuroprotection, and the therapeutic implications of its use.

4. Mechanism of Action

Research indicates that erythravine inhibits the nicotinic receptor subtypes α7 and α4β2, with IC50 values of 6 μM and 13 nM, respectively[15]. Nicotinic receptors are crucial as they significantly contribute to Erythravine's primary role in neurotransmission and neuroprotection by acting as an antagonist of the nicotinic acetylcholine receptor.

Moreover, erythravine exhibits anticonvulsant properties, effectively preventing seizures induced by various convulsants, such as pentylenetetrazole and NMDA[14]. The compound has also been shown to enhance latency in seizure models, suggesting a potential protective effect against excitotoxic events that threaten neuronal integrity.

Additionally, studies involving animal models have revealed the anxiolytic effects of erythravine, indicating that it may influence anxiety-related behaviors through pathways that could involve GABAergic systems[15]. Its

multifaceted activity underscores its promise as a therapeutic option for conditions characterized by stress and neural excitability.

5. The Function of Erythravine in Neuroprotection

Erythravine's neuroprotective effects are linked to several mechanisms:

It has been shown to mitigate oxidative stress by decreasing the buildup of reactive oxygen species (ROS) during cerebral ischemia, thereby lowering the risk of oxidative damage to neurons[16].

- Modulation of Neurotransmitter Systems: Erythravine influences cholinergic signaling, which is vital for memory and cognitive functions, by interacting with nicotinic receptors. This modulation can help restore balance in neurotransmitter systems disrupted by stroke or neurodegenerative diseases[15].
- Diminished Inflammatory Reactions: Anti-inflammatory alkaloids like erythravine may help reduce the damage caused by ischemia in neural tissue[16].

6. Clinical Consequences

Erythravine offers more than just basic neuroprotection. Its ability to prevent seizures suggests it could be beneficial in treating epilepsy and other seizure disorders. Additionally, patients dealing with anxiety stemming from neurological issues might find relief from its anxiolytic properties[14]. While preclinical studies show promising results for erythravine, clinical trials are necessary to assess its safety and effectiveness in humans. The translation of these findings into clinical practice remains unclear. More research is needed to clarify appropriate dosages, methods of administration, and long-term effects, as the relevance of these findings in human subjects is still under investigation[17].

7. Conclusion

There is a strong need for research into the potential of erythravine and other isoflavonoids as neuroprotective agents in stroke treatment. Future studies should focus on clinical trials to confirm preclinical results and determine optimal dosing strategies. Addressing these gaps will be essential for integrating these compounds into standard stroke treatment protocols.

8. References

1. GBD 2019 Stroke Collaborators. Global, regional, and national burden of stroke and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Neurol. 2021;20(10):795-820.
2. Feigin VL, Norrving B, Mensah GA. Global burden of stroke. Circ Res. 2017;120(3):439-448.
3. Li X, Kong X, Yang C, Cheng Z, Lv J, Guo H, Liu X. Global, regional, and national burden of ischemic stroke, 1990–2021: an analysis of data from the Global Burden of Disease Study 2021. Lancet Neurol. 2023;22(6):491-507.
4. Iadecola C, Anrather J. The immunology of stroke: from mechanisms to translation. Nat Rev Immunol. 2011;11(5):360-372.
5. Badhiwala JH, Nassiri F, Alhazzani W, Selim MH, Farrokhyar F, Spears J, Kulkarni AV, Singh S, Alqahtani A, Rochwerg B, Alshahrani M, Murty NK, Alhazzani A, Yarascavitch B, Reddy K, Zaidat OO, Almenawer SA. Endovascular thrombectomy for acute ischemic stroke: a meta-analysis. JAMA. 2015;314(17):1832-1843.
6. Martínez-Coria H, Arrieta-Cruz I, Gutiérrez-Juárez R, López-Valdés HE. Anti-inflammatory effects of flavonoids in common neurological disorders associated with aging. Int J Mol Sci. 2023;24(5):4297.
7. De Bona AP, Batitucci MCP, Andrade MA. Estudo fitoquímico e análise mutagênica das folhas e inflorescências de Erythrina mulungu (Mart. ex Benth.) através do teste de micronúcleo em roedores. Rev Bras Farmacogn. 2012;22(1):92-96.
8. Xicoy H, Wieringa B, Martens GJ. The SH-SY5Y cell line in Parkinson's disease research: a systematic review. Mol Neurodegener. 2017;12(1):10.
9. Koopman G, Reutelingsperger CP, Kuijten GA, Keehnen RM, Pals ST, van Oers MH. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood. 1994;84(5):1415-1420.
10. Shi X, Bai H, Wang J, Wang J, Huang L, He M, Zheng X, Duan Z, Chen D, Zhang J, Chen X, Wang J. Behavioral assessment of sensory, motor, emotion, and cognition in rodent models of intracerebral hemorrhage. Front Neurol. 2021;12:667511.
11. Zeng L, Hu S, Zeng L, Chen R, Li H, Yu J, Yang H. Animal models of ischemic stroke with different forms of middle cerebral artery occlusion. Brain Sci. 2023;13(7):1007.
12. dos Reis SL, Gelfuso EA, Fachin AL, Pereira AMS, Beleboni RO. Pharmacological characterisation of anticonvulsant effects elicited by erythrartine. J Pharm Pharmacol. 2021;73(1):93-97.
13. Fluri F, Schuhmann M, Kleinschnitz C. Animal models of ischemic stroke and their application in clinical research. Drug Des Devel Ther. 2015;9:3445-3454.
14. Faggion SA, Cunha AOS, Fachim HA, Gavin AS, dos Santos WF, Pereira AMS, Beleboni RO. Anticonvulsant profile of the alkaloids (+)-erythravine and (+)-11-α-hydroxy-erythravine isolated from the flowers of Erythrina mulungu Mart ex Benth (Leguminosae–Papilionaceae). Epilepsy Behav. 2011;21(4):431-436.
15. Gelfuso EA, Reis SL, Aguiar DSR, Faggion SA, Gomes FMM, Galan DT, et al. New insights in the mode of action of (+)-erythravine and (+)-11α-hydroxy-erythravine alkaloids. Eur J Pharmacol. 2020;885:173390.
16. Adhikari S, Subhash S, Nayak S, Thomas C, Suryavanshi C. Protection of prefrontal cortex neurons and improvement of memory in epileptic rats by 1-triacontanol cerotate. J Res Pharm. 2024;28(5).
17. Kaur S, Kaur G, Rana R, Kumar B, Melkani I, Kumar S, et al. The therapeutic impact of alkaloids

in neurological diseases: A promising key molecule.
E3S Web Conf. 2024;556:01004.